MONT-SAINT-GUIBERT, Belgium, April 19, 2024 /PRNewswire/ — Cognivia, an artificial intelligence technology company focused on transforming pharmaceutical and biotechnological clinical research with cutting-edge AI-ML algorithms, proudly announces significant investment activities. Vesalius Biocapital IV, SFPIM (Société Fédérale de Participations et d’Investissement), and WE (Wallonie Entreprendre) have strategically invested to support Cognivia’s mission of “quantifying the power of the mind” to optimize and expedite drug development programs. The capital raised will facilitate the implementation of predictive solutions in clinical research, decoding the relationship between patient traits and behaviors, thereby accelerating the development of innovative therapies worldwide.
Cognivia’s technologies target crucial areas that have historically posed significant challenges in drug development, such as placebo response and patient adherence in clinical trials. Unlike other entities, Cognivia pioneers the quantitative perception of patients as individuals and integrates these insights with clinical trial data analysis and/or patient engagement strategies optimization. For instance, Placebell™ utilizes predictive algorithms to mitigate the negative impact of the placebo response, enhancing the research power of clinical trials, resulting in increased success rates, shortened timeframes, and reduced costs. The Compl-AI tool forecasts the risk of non-adherence and patient dropout during screening and throughout clinical trials, aiding in strengthening and personalizing patient recruitment strategies.
The acquired capital will catalyze Cognivia’s efforts to introduce groundbreaking solutions to the market and solidify its position in the United States. By expanding its team and establishing a subsidiary in the US, the company aims to support enhanced trade and research and development collaboration. Future plans involve reinforcing its organizational structure through strategic alliances, expanding the advisory board with new members, and creating teams both in the US and the EU. This strategic move aligns perfectly with Cognivia’s consistent pursuit to become a key partner for pharmaceutical and biotechnological companies, enabling them to develop effective treatment methods to meet current patient needs.
In the latest funding round, Cognivia proudly welcomes the support of three esteemed investors: Vesalius Biocapital IV, a Luxembourg-based venture capital fund specializing in top-notch investments in the HealthTech and biopharmaceutical sectors; SFPIM, a Belgian Sovereign Wealth Fund providing strategic guidance and financial support for Belgian companies; and WE, contributing to the economic development of Wallonia through financing and support across various sectors.
“We are delighted to announce that Cognivia is the inaugural investment of our Fund IV, which focuses on top-tier HealthTech and biopharmaceutical companies driving innovative transformations in healthcare. We look forward to collaborating with them throughout all stages of commercialization and growth,” emphasizes Olivier Houben, Partner at Vesalius Biocapital.
“The strategic agreements between Cognivia and Vesalius Biocapital IV, SFPIM, and WE represent a pivotal moment in our quest to transform the sector through unique utilization of years of industry experience and advanced artificial intelligence,” said Dominique Demolle, CEO/co-founder of Cognivia. “With this investment and the anticipated addition of new members to our operational and management teams and Strategic Advisory Committee, which will be announced soon, we are ready to intensify our efforts to deliver groundbreaking solutions that enable clinicians, researchers, and industry stakeholders to make data-informed decisions, ultimately contributing to improved patient outcomes worldwide.”
Cognivia is the first and only organization that combines the quantification of patients’ psychological traits with artificial intelligence (AI)/machine learning (ML) to enhance, among other aspects, the measurement of therapeutic efficacy in clinical trials. The company’s technologies predict patient behavior and response to treatment in clinical research through predictive algorithms based on ML technology, grounded in a quantitative approach to psychological traits, expectations, and beliefs obtained through customized questionnaires. Cognivia aims to harness the “power of the mind” and quantify this unique phenomenon to improve clinical trial success rates, reduce drug development risks, and ultimately enhance healthcare.
For more information about Cognivia and its groundbreaking AI solutions, visit cognivia.com or follow @cognivia on LinkedIn.
CONTACT:
Stephanie Alvarez
Director of Marketing at Cognivia
Email: [email protected]
Logo – https://mma.prnewswire.com/media/2082754/Cognivia_Logo.jpg
The article discusses Cognivia, an artificial intelligence technology company that aims to revolutionize clinical research by harnessing the power of personality traits. The company has announced significant investment activities, with support from Vesalius Biocapital IV, SFPIM, and WE, to optimize and expedite drug development programs.
Cognivia’s technologies target challenges in drug development such as placebo response and patient adherence in clinical trials. The company utilizes predictive algorithms to mitigate the negative impact of the placebo response with their Placebell™ solution. This enhances the research power of clinical trials, leading to increased success rates, shortened timeframes, and reduced costs. The Compl-AI tool forecasts the risk of non-adherence and patient dropout, aiding in strengthening and personalizing patient recruitment strategies.
With the capital raised, Cognivia plans to introduce groundbreaking solutions to the market and solidify its position in the United States. The company aims to expand its team and establish a subsidiary in the US to support enhanced trade and research and development collaboration. Cognivia also plans to reinforce its organizational structure through strategic alliances, expand its advisory board, and create teams in both the US and the EU.
The investment in Cognivia by Vesalius Biocapital IV, SFPIM, and WE highlights the belief in the company’s potential to drive innovative transformations in healthcare. These investors provide strategic guidance and financial support for Cognivia’s growth and commercialization.
Cognivia is the first organization to combine the quantification of patients’ psychological traits with artificial intelligence and machine learning to enhance the measurement of therapeutic efficacy in clinical trials. Their technologies predict patient behavior and response to treatment through predictive algorithms based on machine learning technology and quantitative psychological traits. The company aims to improve clinical trial success rates, reduce drug development risks, and enhance healthcare outcomes.
Advantages of Cognivia’s approach include improved success rates, shortened timeframes, and reduced costs in clinical trials. By utilizing artificial intelligence and machine learning, the company can provide data-informed decisions for clinicians, researchers, and industry stakeholders, leading to improved patient outcomes.
However, there are also potential challenges and controversies associated with this approach. Some concerns may include the accuracy of predicting patient behavior solely based on quantitative psychological traits and the ethical considerations of using AI and machine learning in healthcare.
For more information about Cognivia and its AI solutions, visit their website at cognivia.com.